232 related articles for article (PubMed ID: 25624175)
1. Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.
Pullarkat V; Aldoss I
Crit Rev Oncol Hematol; 2015 Jul; 95(1):38-45. PubMed ID: 25624175
[TBL] [Abstract][Full Text] [Related]
2. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
3. A strategy of Day14 bone marrows and early intervention is not superior to a strategy of noDay14 bone marrows and delayed intervention in patients with acute myeloid leukemia.
Refaei M; Radhwi O; Sandhu I; Brandwein J; Sun HWL; Saini L
Leuk Lymphoma; 2019 Jul; 60(7):1749-1757. PubMed ID: 31043109
[TBL] [Abstract][Full Text] [Related]
4. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
5. New methods for assessing response in acute myeloid leukemia.
Hall AC; Mattison RJ
Curr Opin Hematol; 2015 Mar; 22(2):132-8. PubMed ID: 25584823
[TBL] [Abstract][Full Text] [Related]
6. Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA; Olszewski AJ; Butera JN; Quesenberry MI; Quesenberry PJ; Reagan JL
Clin Lymphoma Myeloma Leuk; 2018 Mar; 18(3):204-209. PubMed ID: 29433979
[TBL] [Abstract][Full Text] [Related]
7. Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results.
Jamy O; Bodine C; Sampat D; Sarmad R; Chadha A; Vachhani P; Papadantonakis N; Di Stasi A
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):31-38. PubMed ID: 31757719
[TBL] [Abstract][Full Text] [Related]
8. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
Ofran Y
Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
[TBL] [Abstract][Full Text] [Related]
9. Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases.
Alsaleh K; Aleem A; Almomen A; Anjum F; S Alotaibi G
Asian Pac J Cancer Prev; 2018 Feb; 19(2):421-425. PubMed ID: 29479992
[TBL] [Abstract][Full Text] [Related]
10. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
Nachar VR; Perissinotti AJ; Scappaticci GB; Bixby DL; Marini BL
Leuk Res; 2017 Dec; 63():56-61. PubMed ID: 29102597
[TBL] [Abstract][Full Text] [Related]
11. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
12. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
[TBL] [Abstract][Full Text] [Related]
13. Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.
Marani C; Clavio M; Grasso R; Colombo N; Guolo F; Kunkl A; Ballerini F; Giannoni L; Ghiggi C; Fugazza G; Ravetti JL; Gobbi M; Miglino M
Leuk Res; 2013 Dec; 37(12):1606-11. PubMed ID: 23891447
[TBL] [Abstract][Full Text] [Related]
14. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
[TBL] [Abstract][Full Text] [Related]
15. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
16. Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia.
AbdElAal Asmaa A; Afify RA; Zaher AE; ElGammal MM; Atef AM
Hematology; 2015 Oct; 20(9):504-10. PubMed ID: 25885121
[TBL] [Abstract][Full Text] [Related]
17. [Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML].
Jehn U; Dengler R; Petrides PE
Internist (Berl); 1996 Jun; 37(6):661-8. PubMed ID: 8768003
[No Abstract] [Full Text] [Related]
18. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia.
Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Taparia M; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Mirza I; Quest G; Nahirniak S; Ghosh S; Sandhu I
Leuk Res; 2016 Jun; 45():47-52. PubMed ID: 27092851
[TBL] [Abstract][Full Text] [Related]
19. Day 14 bone marrow examination in the management of acute myeloid leukemia.
Terry CM; Shallis RM; Estey E; Lim SH
Am J Hematol; 2017 Oct; 92(10):1079-1084. PubMed ID: 28612456
[TBL] [Abstract][Full Text] [Related]
20. Residual leukemic cell counts in the bone marrow at the end point of intensive induction therapy may be a prognostic factor for acute myeloblastic leukemia in adults.
Fujisawa S; Maruta A; Motomura S; Fukawa H; Kanamori H; Ogawa K; Matsuzaki M; Miyashita H; Harano H; Murata T; Sakai R; Mohri H; Kodama F; Okubo T
Leuk Lymphoma; 1998 Mar; 29(1-2):161-70. PubMed ID: 9638985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
